AcrySof® IQ PanOptix® Trifocal IOL Receives FDA Approval
Today Alcon announced the U.S. Food & Drug Administration approved the AcrySof® IQ PanOptix® Trifocal intraocular lens (IOL)—the first and only IOL approved for the U.S. market and patients undergoing cataract surgery.
PanOptix is currently available in 70+ countries and has been clinically shown to provide a good combination of near, distance, and intermediate vision. It uses ENLIGHTEN® Optical Technology, which optimizes intermediate vision without compromising near and distance vision, and is available in toric and spherical designs.
“We are proud to bring this new class of IOLs to the largest eye care market in the world,” said David J. Endicott, Chief Executive Officer of Alcon. He continued, “We are leveraging Alcon’s years of experience with PanOptix in other countries to provide the best possible training and support for U.S. surgeons. Our goal is to ensure optimal outcomes for cataract patients looking to correct their vision at all distances, with the vast majority of them never needing to wear glasses post-surgery.”
Approval of the lens was based on a study across 12 sites that showed high patient satisfaction; >99% of patients who received the PanOptix lens said they would choose it again. Training of ophthalmologists and providing inventory of the IOL is expected to carry through the rest of 2019 and into 2020.
You can read more here.
